Incidental Detection of Leydig Cell Tumor Via Fluorine-18-Choline PET/CT in a Patient With Recurrent Prostate Cancer Disease

Cimitan, M.; Hodolič, Marina; Maffione, Anna Margherita; Borsatti, Eugenio; Urso, Carmelo; Colletti, Patrick M.; Rubello, Domenico

doi:10.1097/rlu.0b013e31829af8a6

Clinical Nuclear Medicine

2013

DOI: 10.1097/rlu.0b013e31829af8a6

|View full text |Cite

Incidental Detection of Leydig Cell Tumor Via Fluorine-18-Choline PET/CT in a Patient With Recurrent Prostate Cancer Disease

M. Cimitan¹,

Marina Hodolič²,

Anna Margherita Maffione³

et al.

Abstract: We report a case of a 62-year-old man with biochemical recurrence of prostate cancer disease, investigated by fluorine-18-Choline ((18)F-FCH) PET/CT. (18)F-FCH PET/CT demonstrated focal increased uptake of (18)F-FCH inside the right testis, suggestive for distant recurrent disease. On testis removal, a Leydig cell tumor of 2.5 cm in diameter was unexpectedly found. (18)F-FCH PET/CT may demonstrate tumors other than prostate cancer.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 7 publications

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Nuclear medicine imaging modalities to detect incidentalomas and their impact on patient management: a systematic review

Costanzo,

Scalia,

Strigari

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose This systematic review aims to investigate the role of nuclear imaging techniques in detecting incidentalomas and their impact on patient management. Methods Following PRISMA guidelines, a comprehensive literature search was conducted from February to May 2022. Studies in English involving patients undergoing nuclear medicine studies with incidental tumor findings were included. Data on imaging modalities, incidentaloma characteristics, management changes, and follow-up were extracted and analyzed. Results Ninety-two studies involving 64.884 patients were included. Incidentalomas were detected in 611 cases (0.9%), with thyroid being the most common site. PET/CT with FDG and choline tracers showed the highest incidentaloma detection rates. Detection of incidentalomas led to a change in therapeutic strategy in 59% of cases. Various radiotracers demonstrated high sensitivity for incidentaloma detection, particularly in neuroendocrine tumors and prostate cancer. Conclusion Nuclear imaging techniques play a crucial role in detecting incidentalomas, leading to significant changes in patient management. The high sensitivity of these modalities highlights their potential in routine oncology follow-up protocols. Future directions may include enhancing spatial resolution and promoting theranostic approaches for improved patient care.

show abstract

Nuclear medicine imaging modalities to detect incidentalomas and their impact on patient management: a systematic review

Costanzo,

Scalia,

Strigari

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Incidental Leydig Cell Tumor in Patient with Hormone Resistant Prostate Cancer

Pérez¹,

Marrero²,

Lee³

et al. 2017

Urology Case Reports

View full text Add to dashboard Cite

We hereby present the case of a 55 years old patient with clinical diagnosis of high-risk prostate cancer T2bN1Mo Gleason 9 (4 + 5) treated with androgen deprivation therapy and external beam radiotherapy. Despite treatment, castration levels were not achieved and clinical progression was evidenced by the appearance of bone metastases and progression of PSA. After several hormonal treatments without any PSA or testosterone response, surgical castration was performed by bilateral orchiectomy. The pathology results showed an incidental Leydig cell tumor in the right testicle.

show abstract

PET imaging in testicular tumours

Calabrò

Telo²,

Ambrosini³

2020

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of review Testicular cancer is rare, but its incidence is expected to rise. [18F] fluorodeoxyglucose ([18F]FDG) PET/computed tomography (CT) added role in testicular cancer management has been defined in a set of specific clinical settings. The current review focuses on recent advances in the employment of PET/CT in testicular cancer patients. Recent findings [18F]FDG PET/CT is not recommended for initial staging or for suspected testicular tumours. PET/CT role in testicular cancer management is mainly for the assessment of seminoma residual masses after therapy (>3 cm). Although [18F]FDG PET/CT has a very high negative predictive value, its positive predictive value varies across studies: appropriate PET/CT scheduling after therapy and a careful history are mandatory for accurate interpretation. Interim PET/CT could prove valuable to spare subsequent chemotherapy cycles in patients already in remission, reducing related toxicity. The role of [18F]FDG in nonseminoma tumours is hampered by the low sensitivity in teratoma. Summary [18F]FDG PET/CT is currently used for the assessment of seminoma residual masses (>3 cm) after therapy. A negative PET could also spare unnecessary further chemotherapy cycles in responding patients, reducing toxicity. Although rare, testicular secondary lesions can be detected with non[18F]FDG tracers when PET/CT is performed for other primary tumours.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Incidental Detection of Leydig Cell Tumor Via Fluorine-18-Choline PET/CT in a Patient With Recurrent Prostate Cancer Disease

Cited by 7 publications

References 7 publications

Nuclear medicine imaging modalities to detect incidentalomas and their impact on patient management: a systematic review

Nuclear medicine imaging modalities to detect incidentalomas and their impact on patient management: a systematic review

Incidental Leydig Cell Tumor in Patient with Hormone Resistant Prostate Cancer

PET imaging in testicular tumours

Contact Info

Product

Resources

About